Interferon-Free Regimens: The Near Future, the Likely and the Not So Likely

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 665-675

  Shiffman, Mitchell L ^a  

^a Bon Secours Health System   (United States)

Author keywords

Chronic hepatitis C virus; IL28B genotype; Peginterferon; Polymerase inhibitors; Protease inhibitors; Sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

COMBINATION CHEMOTHERAPY; DRUG MECHANISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; NONHUMAN; REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; VIRUS REPLICATION;

EID: 80051917166     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.004     Document Type: Review

References (58)

1. Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989, 321:1506-1510.
2. McHutchinson J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998, 339:1485-1492.
3. Lindsay K.L., Trepo C., Heintges T., et al. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34:395-403.
4. Reddy K.R., Wright T.L., Pockros P.J., et al. Efficacy and safety of pegylated (40-KD) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001, 33:433-438.
5. Heathcote E.J., Shiffman M.L., Cooksley W.G., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
6. Manns M.P., McHutchinson J.G., Gordon S.C., et al. Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
7. Fried M.W., Shiffman M.L., Reddy K.R., et al. Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
8. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
9. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
10. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-134.
11. Weisberg I.S., Jacobson I.M. Telaprevir: hope on the horizon, getting closer. Clin Liver Dis 2009, 13:441-452.
12. Berman K., Kwo P.Y. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009, 13:429-439.
13. Burton J.R., Everson G.T. HCV NS5B polymerase inhibitors. Clin Liver Dis 2009, 13:453-465.
14. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-11206.
15. Jacobson I.M., McHutchison J.G., Dusheiko G.M., et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment naïve patients: final results of phase 3 Advance study. Hepatology 2010, 52(SUPPL):427A.
16. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29(SUPPL 1):74-81.
17. Gane E.J., Roberts S.K., Stedman C.A., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
18. Zeuzem S., Buggisch P., Agarwal K., et al. Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin or Peginterferon/ribavirin for up to 28 days in treatment naïve, genotype 1 HCV subjects. Hepatology 2010, 52(SUPPL):400A.
19. Di Bisceglie A.M., Nelson D.R., Gane E., et al. VX-222 with telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: Zenith study interim results. J Hepatol 2011, 54(SUPPL):S540.
20. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809.
21. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010, 30:555-564.
22. Vilcek J., Zinkernagel R.M., Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science 1993, 259:1742-1745.
23. Hwang S.Y., Hertzog P.J., Holland K.A., et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 1995, 92:11284-11288.
24. Samuel C.E., Kuhen K.L., George C.X., et al. The PKR protein kinase-an interferon-inducible regulator of cell growth and differentiation. Int J Hematol 1997, 65:227-237.
25. Witt P.L., Marie I., Robert N., et al. Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J Interferon Res 1993, 13:17-23.
26. Staeheli P., Pitossi F., Pavlovic J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol 1993, 3:268-272.
27. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007, 27:152-160.
28. Seo Y.J., Hahm B. Type I interferon modulates the battle of host immune system against viruses. Adv Appl Microbiol 2010, 73:83-101.
29. Frese M., Schwarzle V., Barth K., et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
30. Chan H.L., Ren H., Chow W.C., et al. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 2007, 46:315-323.
31. Muir A.J., Shiffman M.L., Zaman A., et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832.
32. Herrmann E., Neumann A.U., Schmidt J.M., et al. Hepatitis C virus kinetics. Antivir Ther 2000, 5:85-90.
33. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
34. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
35. Shiffman M.L., Mihas A.A., Millwala F., et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 2007, 102:1-6.
36. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009, 360:257-267.
37. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
38. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
39. Afdhal N.H., McHutchison J.G., Zeuzem S., et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53:336-345.
40. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
41. Thompson A.J., Muir A.J., Sulkowski M.S., et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology 2010, 139:120-129.
42. Sonneveld M.J., Wong V.W.S., Woltman A.M., et al. Polymorphisms at RS12979860 and RS 12980275 near IL28B predict serological response to INF/Peginterferon in HBEG-positive chronic hepatitis B. J Hepatol 2011, 54(SUPPL):S32.
43. Reddy K.R., Shiffman M.L., Rodriguez-Torres M., et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010, 139:1972-1983.
44. Pockros P., Jacobson I., Boyer T.D., et al. GI-5005 therapeutic vaccine plus peginterferon/ribavirin improves sustained virologic response versus peginterferon/ribavirin in prior non-responders with genotype 1 chronic HCV infection. Hepatology 2010, 52(SUPPL):404A.
45. Shiffman M.L. Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Clin Liver Dis 2008, 12:487-505.
46. Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol, in press.
47. Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
48. Ferenci P., Laferl H., Scherzer T.M., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135:451-458.
49. Lee S.S., Sherman M., Ramji A., et al. 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: final results of a randomized multicenter study. Hepatology 2010, 52(SUPPL):359A.
50. Shiffman M.L. HCV response guided therapy: should treatment length be shortened or extended?. Curr Hepat Rep 2011, 10:4-10.
51. Jacobson I.M., Catlett I., Marcellin P., et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J Hepatol 2011, 54(SUPPL):S542.
52. Poordad F., Bronowicki J.P., Gordon S.C., et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. J Hepatol 2011, 54(SUPPL):S6.
53. Gale M., Katze M.G. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon induced protein kinase. Pharmacol Ther 1998, 78:29-46.
54. Taylor D.R., Shi S.T., Romano P.R., et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
55. Lok A., Gardiner D., Lawitz E., et al. Quadruple therapy with MBS-790052, BMS-650032 and peginterferon/ribavirin for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011, 54(SUPPL):S536.
56. Shiffman M.L. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004, 3:5-10.
57. Guedj J., Perelson A.S. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53(6):1801-1808.
58. Rong L., Dahari H., Ribeiro R.M., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010, 2(30):30ra32.